1 - 3 out of 3Page size: 10
  1. 2018

  2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

    EMPA-REG OUTCOME Investigators, 9 Jan 2018, In: Circulation. 137, 2, p. 119-129 11 p.

    Research output: Contribution to journal › Article › peer-review

  3. 2016

  4. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

    EMPA-REG OUTCOME Investigators, 14 May 2016, In: European Heart Journal. 37, 19, p. 1526-1534 9 p.

    Research output: Contribution to journal › Article › peer-review

  5. 2003

  6. Study of DNA complexation with platinum coordination compounds

    Kas'yanenko, N. A., Abramchuk, S. S., Blagodatskikh, I. V., Bogdanov, A. A., Gallyamov, M. O., Kononov, A. I., Kosmotynskaya, Y. V., Sitnikova, N. L. & Khokhlov, A. R., 2003, In: Polymer Science - Series A. 45, 10, p. 960-968

    Research output: Contribution to journal › Article › peer-review

ID: 14551375